DK2327719T3 - Hybrid and tandem expression of neisseria proteins - Google Patents
Hybrid and tandem expression of neisseria proteinsInfo
- Publication number
- DK2327719T3 DK2327719T3 DK10179755.3T DK10179755T DK2327719T3 DK 2327719 T3 DK2327719 T3 DK 2327719T3 DK 10179755 T DK10179755 T DK 10179755T DK 2327719 T3 DK2327719 T3 DK 2327719T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino acid
- acid sequence
- proteins
- hybrid
- optional
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 241000588653 Neisseria Species 0.000 title 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 abstract 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 abstract 1
- 241001212279 Neisseriales Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Two or more Neisserial proteins are joined such that they are translated as a single polypeptide chain. Hybrid proteins are represented by the formula NH 2 -A-[-X-L-] n -B-COOH where X is an amino acid sequence, L is an optional linker amino acid sequence, A is an optional N-terminal amino acid sequence, B is an optional C-terminal amino acid sequence, and n is an integer greater than 1. Proteins where each of the n -X- moieties shares sequence identity to each other -X- moiety, the protein is a 'tandem protein'.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0121591.2A GB0121591D0 (en) | 2001-09-06 | 2001-09-06 | Hybrid and tandem expression of neisserial proteins |
EP02777592A EP1423419B1 (en) | 2001-09-06 | 2002-09-06 | Hybrid and tandem expression of neisserial proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2327719T3 true DK2327719T3 (en) | 2014-11-03 |
Family
ID=9921633
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10179788.4T DK2360176T3 (en) | 2001-09-06 | 2002-09-06 | Hybrid and tandem expression of neisserialt derived proteins |
DK10179755.3T DK2327719T3 (en) | 2001-09-06 | 2002-09-06 | Hybrid and tandem expression of neisseria proteins |
DK02777592.3T DK1423419T3 (en) | 2001-09-06 | 2002-09-06 | Hybrid and tandem expression of Neisseria proteins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK10179788.4T DK2360176T3 (en) | 2001-09-06 | 2002-09-06 | Hybrid and tandem expression of neisserialt derived proteins |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02777592.3T DK1423419T3 (en) | 2001-09-06 | 2002-09-06 | Hybrid and tandem expression of Neisseria proteins |
Country Status (18)
Country | Link |
---|---|
US (6) | US8980277B2 (en) |
EP (4) | EP2360176B1 (en) |
JP (4) | JP4511832B2 (en) |
CN (2) | CN100390196C (en) |
AT (1) | ATE496063T1 (en) |
AU (2) | AU2002339217B2 (en) |
BR (1) | BR0212363A (en) |
CA (1) | CA2459816C (en) |
CY (2) | CY1113218T1 (en) |
DE (1) | DE60238993D1 (en) |
DK (3) | DK2360176T3 (en) |
ES (3) | ES2357503T3 (en) |
GB (1) | GB0121591D0 (en) |
MX (2) | MXPA04002216A (en) |
NZ (3) | NZ537976A (en) |
PT (3) | PT1423419E (en) |
RU (2) | RU2339646C2 (en) |
WO (1) | WO2003020756A2 (en) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1047784E (en) * | 1998-01-14 | 2009-12-21 | Novartis Vaccines & Diagnostic | Neissera meningitidis antigens |
US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
EP2261346A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
EP2278007B1 (en) | 1999-04-30 | 2014-04-16 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
CA2373236C (en) | 1999-05-19 | 2014-08-26 | Chiron S.P.A. | Combination neisserial compositions |
CA2954411A1 (en) | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
DK1897555T3 (en) * | 2000-01-17 | 2014-10-13 | Novartis Vaccines & Diagnostic | Supplemental OMV vaccine against meningococcus |
DK1947187T5 (en) | 2000-02-28 | 2011-10-24 | Novartis Vaccines & Diagnostic | Hybrid expression of neisserial proteins |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
JP4592284B2 (en) * | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Neisseria meningitidis attachment factor |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
US7838015B2 (en) | 2001-10-03 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
JP4740738B2 (en) * | 2002-08-02 | 2011-08-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | vaccine |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
HUE031886T2 (en) * | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages |
ATE466875T1 (en) | 2002-11-15 | 2010-05-15 | Novartis Vaccines & Diagnostic | UNEXPECTED SURFACE PROTEINS IN NEISSERIA MENINGITIDIS |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
CA2514328C (en) * | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP1670506B1 (en) * | 2003-10-02 | 2012-11-21 | Novartis AG | Liquid vaccines for multiple meningococcal serogroups |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
GB0415160D0 (en) * | 2004-07-06 | 2004-08-11 | Chiron Srl | Inhibitors of bacterial infection |
GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
EP1858919B1 (en) | 2005-02-18 | 2012-04-04 | Novartis Vaccines and Diagnostics, Inc. | Immunogens from uropathogenic escherichia coli |
EP1858920B1 (en) | 2005-02-18 | 2016-02-03 | GlaxoSmithKline Biologicals SA | Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli |
AU2013201318B2 (en) * | 2005-11-25 | 2015-11-19 | Glaxosmithkline Biologicals Sa | Chimeric, hybrid and tandem polypeptides of meningococcal NMB 1870 |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
WO2007066226A2 (en) * | 2005-12-06 | 2007-06-14 | Universita Degli Studi Di Padova | Methods and compositions relating to adhesins as adjuvants |
EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
PL2200642T3 (en) | 2007-10-19 | 2012-09-28 | Novartis Ag | Meningococcal vaccine formulations |
AU2009215364B2 (en) | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
US8466167B2 (en) | 2008-03-03 | 2013-06-18 | Irm Llc | Compounds and compositions as TLR activity modulators |
CA2717870A1 (en) * | 2008-03-10 | 2009-09-17 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
CA2726512A1 (en) * | 2008-06-09 | 2009-12-17 | Novartis Ag | Antibodies against neisserial factor h binding protein |
BRPI0923006A2 (en) * | 2008-12-17 | 2016-03-08 | Novartis Ag | meningococcal vaccines including hemoglobin receptor |
DK2411048T3 (en) | 2009-03-24 | 2020-06-15 | Glaxosmithkline Biologicals Sa | ADJUSTIVE MENINGOCOC FACTOR H BINDING PROTEIN |
BRPI1013902A2 (en) * | 2009-04-30 | 2019-09-24 | Children´S Hospital & Res Center At Oakland | chimeric factor binding protein h (fhbp) is method of use |
CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
ES2596653T3 (en) | 2009-06-16 | 2017-01-11 | Glaxosmithkline Biologicals Sa | Opsonization bactericidal and antibody-dependent assays mediated by high-performance complement |
US20110076300A1 (en) | 2009-08-27 | 2011-03-31 | Mariagrazia Pizza | Hybrid Polypeptides Including Meningococcal fHBP Sequences |
CA2772916C (en) | 2009-09-02 | 2019-01-15 | Novartis Ag | Immunogenic compositions including tlr activity modulators |
JO3257B1 (en) | 2009-09-02 | 2018-09-16 | Novartis Ag | Compounds and compositions as tlr activity modulators |
CA2776004A1 (en) | 2009-09-30 | 2011-04-07 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
US20130022633A1 (en) | 2009-10-27 | 2013-01-24 | University Of Florence | MENINGOCOCCAL fHBP POLYPEPTIDES |
WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
CN102762206A (en) | 2009-12-15 | 2012-10-31 | 诺华有限公司 | Homogeneous suspension of immunopotentiating compounds and uses thereof |
JP5363381B2 (en) * | 2010-03-09 | 2013-12-11 | パナソニック株式会社 | Plasma display panel |
CN102905703B (en) | 2010-03-23 | 2016-09-28 | 诺华股份有限公司 | As TLR2 agonist for treating compound (lipopeptid based on cysteine) and the compositions of infection, inflammation, respiratory disorder etc. |
ES2661569T3 (en) | 2010-03-30 | 2018-04-02 | Children's Hospital & Research Center At Oakland | H-factor binding proteins (fHbp) with altered properties and methods of use thereof |
CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
AU2011294776B2 (en) | 2010-08-23 | 2016-02-04 | Wyeth Llc | Stable formulations of Neisseria meningitidis rLP2086 antigens |
CA2809758C (en) | 2010-09-10 | 2021-07-13 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
US9259462B2 (en) | 2010-09-10 | 2016-02-16 | Glaxosmithkline Biologicals Sa | Developments in meningococcal outer membrane vesicles |
CN102028941B (en) * | 2011-02-11 | 2013-02-13 | 中国医学科学院医学生物学研究所 | Neisseria meningitidis group B recombinant protein chimeric vaccine and preparation method thereof |
US20140186861A1 (en) * | 2011-07-11 | 2014-07-03 | Uvic Industry Partnerships Inc. | Soluble treponema pallidum protein tp0453, tp0453-tp0326 fusion protein, and use in syphilis diagnosis |
CA2862247A1 (en) | 2011-12-29 | 2013-07-04 | Novartis Ag | Adjuvanted combinations of meningococcal factor h binding proteins |
EP4043029A1 (en) | 2012-03-09 | 2022-08-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (en) | 2012-03-09 | 2017-04-12 | فايزر انك | Neisseria meningitidis compositions and methods thereof |
RU2644340C2 (en) | 2012-06-14 | 2018-02-08 | Новартис Аг | Vaccines for serogroup x meningococcus |
AU2013295242C1 (en) | 2012-07-27 | 2018-08-09 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
ES2685894T3 (en) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Immunogenic fusion polypeptides |
AU2014296027A1 (en) * | 2013-08-02 | 2016-02-04 | Children's Hospital & Research Center At Oakland | Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof |
MX369534B (en) | 2013-09-08 | 2019-11-11 | Pfizer | Neisseria meningitidis compositions and methods thereof. |
US10392424B2 (en) | 2014-02-28 | 2019-08-27 | Glaxosmithkline Biologicals Sa | Modified meningococcal fHbp polypeptides |
CR20170020A (en) | 2014-07-23 | 2017-08-10 | Children´S Hospital & Res Center At Oakland | VARIANTS OF PROTEIN UNIONS TO FACTOR H AND METHODS OF USE OF THESE |
RU2723045C2 (en) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Compositions of neisseria meningitidis and methods for preparation thereof |
CA3035320A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
MX2019009011A (en) | 2017-01-31 | 2019-09-26 | Pfizer | Neisseria meningitidis compositions and methods thereof. |
AU2022223712A1 (en) | 2021-02-19 | 2023-10-05 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
GB202115151D0 (en) | 2021-10-21 | 2021-12-08 | Glaxosmithkline Biologicals Sa | Methods |
GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
TW202423477A (en) | 2022-08-03 | 2024-06-16 | 美商賽諾菲巴斯德公司 | Adjuvanted immunogenic composition against neisseria meningitidis b |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE63757T1 (en) | 1985-03-28 | 1991-06-15 | Chiron Corp | EXPRESSION THROUGH USE OF FUSION GENES FOR PROTEIN PRODUCTION. |
DE3622221A1 (en) * | 1986-07-02 | 1988-01-14 | Max Planck Gesellschaft | METHOD FOR THE GENE-TECHNOLOGICAL EXTRACTION OF PROTEINS USING GRAM-NEGATIVE HOST CELLS |
EP0273116A3 (en) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Gonococcal and meningococcal polypeptides, vaccines and diagnostics |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
ATE120093T1 (en) | 1988-12-19 | 1995-04-15 | Praxis Biolog Inc | MENINGOCOCCALES CLASS I OUTER MEMBRANE PROTEIN VACCINE. |
NL8803111A (en) | 1988-12-19 | 1990-07-16 | Nederlanden Staat | Meningococcus class 1 outer-membrane protein vaccine - useful to immunise against meningococcal disease |
CA2006700A1 (en) | 1989-01-17 | 1990-07-17 | Antonello Pessi | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
EP0504202B1 (en) * | 1989-12-14 | 1995-05-03 | National Research Council Of Canada | Improved meningococcal polysaccharide conjugate vaccine |
CU22302A1 (en) | 1990-09-07 | 1995-01-31 | Cigb | Codifying nucleotidic sequence for a protein of the external membrane of neisseria meningitidis and the use of that protein in preparing vaccines. |
IE912559A1 (en) | 1990-07-19 | 1992-01-29 | Merck & Co Inc | The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same |
ATE128628T1 (en) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE. |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
DE69227898T2 (en) | 1991-03-14 | 1999-05-12 | Imclone Systems, Inc., New York, N.Y. | RECOMBINANT HYBRID PORINE PITOPE |
EP0967279B1 (en) | 1992-03-02 | 2008-01-02 | Novartis Vaccines and Diagnostics S.r.l. | Helicobacter pylori cytotoxin useful for vaccines and diagnostics |
IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
FR2692592B1 (en) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | DNA fragments encoding the Neisseria meningitidis transferrin receptor subunits and methods of expressing them. |
NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
PL178578B1 (en) | 1993-03-23 | 2000-05-31 | Smithkline Beecham Biolog | Composition of vaccines containing 3-0-deacylated monophosphoryl lipoid a |
US5439808A (en) | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6165747A (en) | 1993-12-30 | 2000-12-26 | President & Fellows Of Harvard College | Nucleic acids encoding hedgehog proteins |
FR2720408B1 (en) | 1994-05-31 | 1996-08-14 | Pasteur Merieux Serums Vacc | Fragments Tbp2 of Neisseria meningitidis. |
DK0772619T4 (en) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
IL117483A (en) * | 1995-03-17 | 2008-03-20 | Bernard Brodeur | Proteinase k resistant surface protein of neisseria meningitidis |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
FR2739624B1 (en) | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | NEW NEISSERIA MENINGITIDIS TBP2 SUBUNIT |
CU22559A1 (en) * | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | EXPRESSION SYSTEM OF HETEROLOGICAL ANTIGENS IN E. COLI AS FUSION PROTEINS |
DE19630390A1 (en) | 1996-07-26 | 1998-01-29 | Chiron Behring Gmbh & Co | Proteins, in particular membrane proteins from Helicobacter pylori, their production and use |
ATE292980T1 (en) | 1996-10-11 | 2005-04-15 | Univ California | IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES |
AU5426098A (en) | 1996-10-24 | 1998-05-15 | Emory University | Invasion associated genes from (neisseria meningitidis) serogroup |
US6214806B1 (en) | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
EP1005368B1 (en) | 1997-03-10 | 2009-09-02 | Ottawa Hospital Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US6339068B1 (en) | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
EP2085090A3 (en) | 1997-06-06 | 2012-05-02 | The Regents of the University of California | Inhibitors of DNA immunostimulatory sequence activity |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
CA2302554C (en) | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
CA2308606A1 (en) * | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
BR9814878A (en) | 1997-11-21 | 2000-10-03 | Genset Sa | Genetic sequence and polypeptides of chlamydia pneumoniae, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
WO1999028475A2 (en) | 1997-11-28 | 1999-06-10 | Genset | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
PT1047784E (en) * | 1998-01-14 | 2009-12-21 | Novartis Vaccines & Diagnostic | Neissera meningitidis antigens |
KR100627590B1 (en) | 1998-01-30 | 2006-09-25 | 다이이치 아스비오파마 가부시키가이샤 | Process for producing peptide with the use of accessory peptide |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
GB9807721D0 (en) | 1998-04-08 | 1998-06-10 | Chiron Spa | Antigen |
JP2002511423A (en) | 1998-04-09 | 2002-04-16 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | vaccine |
EP2261346A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
US20070026021A1 (en) | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
MXPA01003557A (en) | 1998-10-09 | 2004-04-05 | Chiron Corp | Neisseria genomic sequences and methods of their use. |
CA2347099C (en) | 1998-10-16 | 2014-08-05 | Smithkline Beecham Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
DK1535928T3 (en) | 1998-10-22 | 2008-10-20 | Univ Montana | Vaccine Compositions Containing Omp85 Proteins of Neisseria gonorrhoeae and Neisseria meningitidis |
EP1133572A4 (en) | 1998-11-12 | 2005-06-15 | Univ California | Chlamydia pneumoniae genome sequence |
GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
FR2791895B1 (en) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE |
AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
TR200103018T2 (en) | 1999-04-19 | 2002-02-21 | Beecham Biologicals S.A. Smithkline | Additive compounds containing immunostimulatory oligonucleotide and saponin. |
CN1359426A (en) | 1999-04-30 | 2002-07-17 | 希龙公司 | Neisseria genomic sequences and methods of their use |
EP2278007B1 (en) | 1999-04-30 | 2014-04-16 | Novartis Vaccines and Diagnostics S.r.l. | Conserved neisserial antigens |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
CA2373236C (en) | 1999-05-19 | 2014-08-26 | Chiron S.P.A. | Combination neisserial compositions |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
IL148672A0 (en) | 1999-09-24 | 2002-09-12 | Smithkline Beecham Biolog | Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
TR200200777T2 (en) | 1999-09-24 | 2002-09-23 | Smithkline Beecham Biologicals S.A. | At least one non-ionic surfactant adjuvant with polyoxyethylene alkyl ether or ester. |
CA2954411A1 (en) | 1999-10-29 | 2001-05-03 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigenic peptides |
DK1897555T3 (en) | 2000-01-17 | 2014-10-13 | Novartis Vaccines & Diagnostic | Supplemental OMV vaccine against meningococcus |
BR0107857A (en) | 2000-01-25 | 2002-10-29 | Univ Queensland | Proteins comprising conserved regions of neisseria meningitidis surface antigen |
DK1947187T5 (en) * | 2000-02-28 | 2011-10-24 | Novartis Vaccines & Diagnostic | Hybrid expression of neisserial proteins |
US20040167058A1 (en) * | 2000-06-29 | 2004-08-26 | Colgate-Palmolive Company | Multi-phase clear fabric softening composition |
WO2002002606A2 (en) | 2000-07-03 | 2002-01-10 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
SG165981A1 (en) | 2000-10-27 | 2010-11-29 | Chiron Srl | Nucleic acids and proteins from streptococcus groups a & b |
GB0108024D0 (en) | 2001-03-30 | 2001-05-23 | Chiron Spa | Bacterial toxins |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
CN100350972C (en) | 2001-07-26 | 2007-11-28 | 启龙股份公司 | Vaccines comprising aluminium adjuvants and histidine |
JP4592284B2 (en) | 2001-07-27 | 2010-12-01 | カイロン ソチエタ ア レスポンサビリタ リミタータ | Neisseria meningitidis attachment factor |
GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
JP4740738B2 (en) | 2002-08-02 | 2011-08-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | vaccine |
US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
EP1590459A2 (en) | 2003-01-15 | 2005-11-02 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression and compositions thereof |
CA2514328C (en) | 2003-01-30 | 2020-01-14 | Chiron Srl | Injectable vaccines against multiple meningococcal serogroups |
US20070253964A1 (en) | 2003-04-16 | 2007-11-01 | Zlotnick Gary W | Novel Immunogenic Compositions for the Prevention and Treatment of Meningococcal Disease |
EP1670506B1 (en) | 2003-10-02 | 2012-11-21 | Novartis AG | Liquid vaccines for multiple meningococcal serogroups |
GB0409748D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
GB0419408D0 (en) | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
AR051836A1 (en) | 2004-11-30 | 2007-02-14 | Centocor Inc | RECEIVER ANTAGONISTS 3 SIMIL TOLL METHODS AND USES |
AU2006208208B2 (en) | 2005-01-27 | 2011-05-19 | Children's Hospital & Research Center At Oakland | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AR064642A1 (en) | 2006-12-22 | 2009-04-15 | Wyeth Corp | POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD |
WO2008125985A2 (en) | 2007-04-11 | 2008-10-23 | Novartis Ag | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
CA2688268A1 (en) | 2007-06-04 | 2008-12-11 | Novartis Ag | Formulation of meningitis vaccines |
AU2009215364B2 (en) | 2008-02-21 | 2014-09-18 | Glaxosmithkline Biologicals S.A. | Meningococcal fHBP polypeptides |
CA2717870A1 (en) | 2008-03-10 | 2009-09-17 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
IT1394288B1 (en) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | PROTEIN IMMUNOGENES THAT LINK THE FACTOR H. |
GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
DK2411048T3 (en) | 2009-03-24 | 2020-06-15 | Glaxosmithkline Biologicals Sa | ADJUSTIVE MENINGOCOC FACTOR H BINDING PROTEIN |
US9259462B2 (en) | 2010-09-10 | 2016-02-16 | Glaxosmithkline Biologicals Sa | Developments in meningococcal outer membrane vesicles |
-
2001
- 2001-09-06 GB GBGB0121591.2A patent/GB0121591D0/en not_active Ceased
-
2002
- 2002-09-06 MX MXPA04002216A patent/MXPA04002216A/en active IP Right Grant
- 2002-09-06 BR BR0212363-0A patent/BR0212363A/en not_active Application Discontinuation
- 2002-09-06 DK DK10179788.4T patent/DK2360176T3/en active
- 2002-09-06 CA CA2459816A patent/CA2459816C/en not_active Expired - Fee Related
- 2002-09-06 EP EP10179788.4A patent/EP2360176B1/en not_active Expired - Lifetime
- 2002-09-06 ES ES02777592T patent/ES2357503T3/en not_active Expired - Lifetime
- 2002-09-06 CN CNB028221877A patent/CN100390196C/en not_active Expired - Fee Related
- 2002-09-06 PT PT02777592T patent/PT1423419E/en unknown
- 2002-09-06 AT AT02777592T patent/ATE496063T1/en active
- 2002-09-06 EP EP10179755.3A patent/EP2327719B1/en not_active Revoked
- 2002-09-06 PT PT101797884T patent/PT2360176E/en unknown
- 2002-09-06 CN CN200810092103XA patent/CN101260148B/en not_active Expired - Fee Related
- 2002-09-06 DK DK10179755.3T patent/DK2327719T3/en active
- 2002-09-06 ES ES10179755.3T patent/ES2523365T3/en not_active Expired - Lifetime
- 2002-09-06 WO PCT/IB2002/003904 patent/WO2003020756A2/en active IP Right Grant
- 2002-09-06 JP JP2003525026A patent/JP4511832B2/en not_active Expired - Fee Related
- 2002-09-06 RU RU2004110230/13A patent/RU2339646C2/en not_active IP Right Cessation
- 2002-09-06 PT PT101797553T patent/PT2327719E/en unknown
- 2002-09-06 DK DK02777592.3T patent/DK1423419T3/en active
- 2002-09-06 AU AU2002339217A patent/AU2002339217B2/en active Active
- 2002-09-06 DE DE60238993T patent/DE60238993D1/en not_active Expired - Lifetime
- 2002-09-06 NZ NZ537976A patent/NZ537976A/en not_active IP Right Cessation
- 2002-09-06 EP EP02777592A patent/EP1423419B1/en not_active Expired - Lifetime
- 2002-09-06 NZ NZ547145A patent/NZ547145A/en not_active IP Right Cessation
- 2002-09-06 US US10/488,786 patent/US8980277B2/en active Active
- 2002-09-06 EP EP14172613.3A patent/EP2829549A3/en not_active Withdrawn
- 2002-09-06 ES ES10179788.4T patent/ES2556770T3/en not_active Expired - Lifetime
- 2002-09-06 NZ NZ532115A patent/NZ532115A/en not_active IP Right Cessation
- 2002-09-06 RU RU2008122435/10A patent/RU2475495C2/en not_active IP Right Cessation
-
2004
- 2004-03-08 MX MX2012000967A patent/MX336118B/en unknown
-
2005
- 2005-09-05 JP JP2005256658A patent/JP2005350486A/en not_active Withdrawn
-
2008
- 2008-10-24 AU AU2008234959A patent/AU2008234959B2/en not_active Ceased
-
2010
- 2010-07-23 JP JP2010166543A patent/JP5542276B2/en not_active Expired - Fee Related
-
2011
- 2011-04-15 CY CY20111100383T patent/CY1113218T1/en unknown
- 2011-06-13 US US13/159,370 patent/US9011869B2/en not_active Expired - Fee Related
-
2012
- 2012-02-03 US US13/366,252 patent/US8840907B2/en not_active Expired - Fee Related
-
2013
- 2013-09-24 JP JP2013196675A patent/JP2014051497A/en not_active Withdrawn
-
2014
- 2014-06-16 US US14/305,979 patent/US9056075B2/en not_active Expired - Fee Related
-
2015
- 2015-06-15 US US14/739,985 patent/US20150273044A1/en not_active Abandoned
- 2015-12-22 CY CY20151101166T patent/CY1117065T1/en unknown
-
2017
- 2017-11-02 US US15/802,347 patent/US20180169210A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2327719T3 (en) | Hybrid and tandem expression of neisseria proteins | |
CY1118037T1 (en) | ANTIBODIES AGAINST AVETA AND THEIR USE | |
NO20063026L (en) | antibodies | |
CY1118443T1 (en) | ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES | |
LTPA2016028I1 (en) | Immunoglobulin chimeric monomer-dimer hybrids | |
DE60238472D1 (en) | WEAKNESS OF IMMUNOGENICITY OF FUSION PROTEINS | |
CY1106875T1 (en) | NEISSERIA ANTIGONAL PIPES | |
BRPI0515649B8 (en) | Process for preparing highly concentrated monoclonal antibody compositions | |
BR0108713A (en) | Hybrid Expression of Neisserial Proteins | |
ATE454393T1 (en) | EGVII-ENDOGLUCANASE AND NUCLEIC ACIDS CODING THEREOF | |
ATE368688T1 (en) | PEPTIDES, THEIR PRODUCTION AND USE FOR BINDING IMMUNOGLOBULINS | |
DE60232577D1 (en) | OLIGOMERIC COMPLEXES OF CHIMERIC PROTEINS WITH IMPROVED IMMUNOGENIC POTENTIAL | |
ATE485386T1 (en) | CYSTEINE-CONTAINING PEPTIDE TAG FOR SITE-SPECIFIC CONJUGATION OF PROTEINS | |
DE60043620D1 (en) | MAGE-A1 PEPTIDES PRESENTED BY CLASS II HLA MOLECULE | |
DK1773994T3 (en) | polypeptide | |
DE69915320D1 (en) | IMMUNOGLOBULIN-BINDING PROTEINS | |
ATE211391T1 (en) | USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH CYTOTOXIC ACTION | |
EA200600042A1 (en) | METHODS OF FORMATION OF DISULFIDIC LINKS AND GLYCOSYLATION OF PROTEINS AND REAGENTS USED IN THESE METHODS | |
ATE466874T1 (en) | POLYPEPTIDES RELATED TO DOMAIN 1 SCYTOVIRIN | |
ES2100960T3 (en) | PROTEIN STRUCTURE OF GELONIN VEGETABLE TOXIN. | |
DE60321443D1 (en) | Screening method for a prophylactic and therapeutic substance for kidney disease | |
CY1115969T1 (en) | PROCEDURE FOR CONCENTRATION OF THEIR ANTIBODIES AND THERAPEUTIC PRODUCTS | |
WO2004058811A3 (en) | Crystal structures of yhhf polypeptides | |
WO2004058812A3 (en) | Ribose-phosphate pyrophosphokinase polypeptides and structures |